Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Peregrine Pharmaceuticals has initiated a phase I anti-viral study of its drug Tarvacin, in patients with chronic hepatitis C virus infection who are not helped by standard therapy.
Subscribe to our email newsletter
The phase I study is an open-label, dose-escalation study in up to 32 adults with hepatitis C; the objectives of the trial are to evaluate safety, pharmacokinetics and viral load following a single intravenous infusion. The study is being conducted at Bach and Godofsky Infectious Diseases, the largest private infectious disease practice specializing in the treatment of viral hepatitis in the US.
“This study is an important step for our Tarvacin antiviral program,” said Joseph Shan, Peregrine’s senior director of clinical and regulatory affairs. “Meanwhile, we are continuing our Tarvacin development efforts for other viral diseases.”
Peregrine Pharmaceuticals is a biopharmaceutical company with a broad portfolio of products under development directed towards the treatment of cancer, viruses and other diseases.